Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 3/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.41 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.40 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.38 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27310588 | 0.79 | MKNK1 (0.54) | MAP4K4GSK3BMAPKAPK2CYP11B2MINK1 | |
| SCHEMBL1840418 | 0.77 | MAP4K4 (0.40) | MAP4K4CCNB2CDK1CCNB1GSK3A | |
| SCHEMBL13730604 | 0.76 | NOS3 (0.52) | MAP4K4GSK3BCYP3A4NOS3NOS2 | |
| SCHEMBL11901650 | 0.76 | MAP4K4 (0.46) | MAP4K4NOS3NOS2MINK1TNIK | |
| SCHEMBL17555671 | 0.76 | CDK2 (0.43) | MAP4K4CDK1CCNB1GSK3AGSK3B | |
| SCHEMBL1165179 | 0.75 | GSK3B (0.47) | MAP4K4GSK3AGSK3BCDK5NOS3 | |
| SCHEMBL5973721 | 0.75 | MAPT (0.47) | MAP4K4NOS3NOS2FYNKDR | |
| Iodide SCHEMBL31385461 | 0.73 | MAPT (0.46) | MAP4K4NOS3NOS2FYNKDR | |
| SCHEMBL5319523 | 0.73 | NOS2 (0.44) | NOS3NOS2KDR | |
| SCHEMBL21928359 | 0.71 | EGLN2 (0.43) | CCNB2CDK1CCNB1GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| CN-102143746-A | CDK modulators | EXELIXIS INC | 2011-08-03 | — | — | CN | disclosed |
| EP-2320895-A2 | CDK MODULATORS | Exelixis, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010003133-A2 | CDK MODULATORS | EXELIXIS INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010003133-A2 | CDK MODULATORS | EXELIXIS INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| CN-1032648-C | Process for preparation of platelet activating factor antagonist | FIZER LTD (GB) | 1996-08-28 | — | — | CN | disclosed |
| CN-1032439-A | A kind of preparation method of platelet-activating factor antagonist | PFIZER LTD (GB) | 1989-04-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201599-A1 | CDK Modulators | CDK3, CDK1, CDKL1 | MAP4K4 174/4885CCNB2 40/4885CDK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.